정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1339 | Completed | Glucocorticoids in COVID-19 (CORTIVID) | Covid-19 Pneumonia | Drug: Methylprednisolone Other: Placebo |
Phase 3 | Fundacion Miguel Servet, Complejo Hospitalario de Navarra, Hospital Sant Joan Despi Moises Broggi | OTHER | 72 | All | 18 Years ~ 75 Years | Hospital Sant Joan Despi Moises Broggi, Sant Joan Despi, Barcelona, Spain Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain |
| 1338 | Recruiting | GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia | COVID-19 Pneumonia | Drug: Molgramostim nebuliser solution Other: Placebo nebuliser solution |
Phase 2 | University of Giessen | OTHER | 238 | All | 18 Years | Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany Universitatsklinikum Essen, Essen, Germany Krankenhaus Nordwest GmbH, Frankfurt am Main, Germany Universitatsklinikum Frankfurt, Frankfurt am Main, Germany Universitatsklinikum Giessen und Marburg GmbH, Standort Giessen, Gießen, Germany Medizinische Hochschule Hannover, Hannover, Germany Universitatsklinikum Heidelberg, Heidelberg, Germany Lungenfachklinik Immenhausen, Immenhausen, Germany Sana Klinikum Offenbach, Offenbach am Main, Germany |
| 1337 | Completed | GRAd-COV2 Vaccine Against COVID-19 | COVID-19 | Biological: GRAd-COV2 | Phase 1 | ReiThera Srl, Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani | INDUSTRY | 90 | All | 18 Years ~ 85 Years | INMI Spallanzani, Rome, Italy Centro Ricerche Cliniche, Verona, Italy |
| 1336 | Withdrawn | Growth Hormone in Obese Cases With Covid-19 | Covid19 | Drug: Growth Hormone Drug: Placebo |
Phase 4 | ClinAmygate | OTHER | 0 | All | 18 Years | Asalam, Maadi, Cairo, Egypt |
| 1335 | Not yet recruiting | Halodine Nasal Antiseptic in Patients With COVID-19 | SARS-CoV-2 Infection | Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP | Phase 4 | Halodine LLC | INDUSTRY | 40 | All | 18 Years | |
| 1334 | Recruiting | Hamburg Edoxaban for Anticoagulation in COVID-19 Study | Covid19 | Drug: Anticoagulation Agents (Edoxaban and/or high dose LMWH) Drug: Low dose Low molecular weight heparin or Placebo |
Phase 3 | Universitatsklinikum Hamburg-Eppendorf | OTHER | 172 | All | 18 Years | Universitatsklinikum Dusseldorf, Dusseldorf, Germany Universitatsklinikum Freiburg, Freiburg, Germany Marienkrankenhaus, Hamburg, Germany Universitarsklinikum Hamburg-Eppendorf, Hamburg, Germany Medizinische Hochschule Hannover, Hanover, Germany Krankenhaus Koln-Merheim, Koln, Germany TU Munchen Klinikum rechts der Isar, Munchen, Germany Universitatsklinikum Munster, Munster, Germany |
| 1333 | Recruiting | Handling Oxygenation Targets in COVID-19 | Oxygen Toxicity | Drug: Oxygen Drug: Oxygen |
Phase 4 | Aalborg University Hospital, Rigshospitalet, Denmark, Copenhagen Trial Unit, Center for Clinical Intervention Research | OTHER | 780 | All | 18 Years | Dept. of Intensive Care, Aalborg University Hospital, Aalborg, Denmark Dept. of Intensive Care 4131, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark Dept. of Intensive Care, Herlev Hospital, Herlev, Denmark Dept. of Intensive Care, Hillerød Hospital, Hillerød, Denmark Dept. of Intensive Care, Kolding Hospital, Kolding, Denmark Dept. of Intensive Care, Køge Hospital, Køge, Denmark Randers Hospital, Randers, Denmark Dept. of Intensive Care, Slagelse Hospital, Slagelse, Denmark Oslo University Hospital, Oslo, Norway Universitatsspital Basel, Basel, Switzerland |